Create
Log in
Enquire now
AbSci
AbSci is an e. Coli expression system for protein production founded in 2011 by Sean McClain.
Overview
Structured Data
Issues
Contributors
Access by API
Access by API
Is a
Organization
Company
B2X
B2B
CEO
Sean McClain
CIK Number
1,672,688
Legal Name
Absci Corporation
Company Operating Status
Active
Competitors
AbCellera Biologics
Country
United States
Crunchbase URL
crunchbase.com/organiz...on/absci
Date Incorporated
2011
DUNS Number
78413876
Email Address
info@absci.com
0
Facebook URL
@abscibio
Founded Date
2011
0
Founder
Sean McClain
Full Address
101 E 6th St, Vancouver, WA 98660, US
Industry
Biotechnology
Engineering
Artificial Intelligence (AI)
0
Technology
Synthetic biology
Biology
Drug development
0
Biomanufacturing
Biomedical engineering
Invested in
Casdin Capital
Phoenix Venture Partners
Investors
Oregon Venture Fund
WRF Capital
KBI Biopharma
Merck Global Health Innovation Fund
Phoenix Venture Partners
Greenbridge Partners
Essential Consultants, LLC
Corporation Ventures
AGC
The R-Group, LLC
•••
Latest Funding Round Date
July 22, 2021
Latest Funding Round Amount (USD)
200,000,000
Latest Funding Type
Initial public offering (IPO)
LinkedIn URL
@company/absci
Location
Vancouver
Vancouver, Washington
Number of Employees
212
0
Number of Employees (Ranges)
51 – 200
0
Patents Assigned (Count)
1
Phone Number
+15032087882
0
+13609491041
Pitchbook URL
pitchbook.com/profiles...153409-96
Ticker Symbol
ABSI
Total Funding Amount (USD)
437,899,976
Official Website
absci.com
YouTube Channel
youtube.com/c/absci
Find more companies like AbSci
Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Company
Home
Press & Media
Blog
Careers
WE'RE HIRING
Products
Knowledge Graph
Query Tool
Data Requests
Knowledge Storage
API
Pricing
Enterprise
ChatGPT Plugin
Legal
Terms of Service
Enterprise Terms of Service
Privacy Policy
Help
Help center
API Documentation
Contact Us
By using this site, you agree to our
Terms of Service
.
SUBSCRIBE